Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.50 (6.25%)
Market Cap: £59.93m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

Form 8.3 - Poolbeg Pharma plc

13 Jan 2025 18:28

RNS Number : 1599T
Poolbeg Pharma PLC
13 January 2025
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Michael Kelly

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Poolbeg Pharma plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

N/A

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

13 January 2025

 

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Ordinary Shares of 0.02p

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

34,714,941

 

6.94%

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

34,714,941

 

6.94%

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

 

Details, including nature of the rights concerned and relevant percentages:

 

 

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

None

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

13 January 2025

Contact name:

Michael Kelly

Telephone number*:

N/A

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETZZGMMRFGGKZM
Date   Source Headline
11th May 20232:27 pmRNSResults of Annual General Meeting
12th Apr 20237:00 amRNSAnnual Report & AGM Notice
30th Mar 20237:00 amRNSResults for the year ended 31 December 2022
10th Mar 20237:00 amRNSNotification of Major Holdings
9th Mar 20233:51 pmRNSNotification of Major Holdings
8th Mar 20237:00 amRNSPOLB 001 patent portfolio strengthened
2nd Mar 202311:05 amRNSSecond Price Monitoring Extn
2nd Mar 202311:00 amRNSPrice Monitoring Extension
2nd Mar 20237:00 amRNSPositive Results POLB001 LPS Human Challenge Trial
16th Jan 20237:00 amRNSStrategic expansion of POLB 001 into oncology
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSPositive Initial Data Analysis in POLB 001 Trial
22nd Dec 202210:48 amEQSPoolbeg Pharma identifies new RSV drug candidates
21st Dec 20227:00 amRNSPoolbeg identifies novel RSV drug candidates
15th Dec 20229:49 amEQSPoolbeg Pharma makes 'interesting addition to existing collaboration'
14th Dec 20227:00 amRNSMetabolic diseases oral delivery licence signed
12th Dec 20222:05 pmRNSSecond Price Monitoring Extn
12th Dec 20222:00 pmRNSPrice Monitoring Extension
12th Dec 202212:00 pmEQSPoolbeg Pharma receives initial results from human challenge clinical study
12th Dec 20227:00 amRNSPOLB 001 LPS human challenge trial completed
29th Nov 20227:00 amRNSInfluenza AI model build completed
21st Nov 202211:37 amEQSPoolbeg Pharma wins first non-dilutive grant funding
18th Nov 20222:00 pmRNSPrice Monitoring Extension
17th Nov 20222:05 pmRNSSecond Price Monitoring Extn
17th Nov 20222:00 pmRNSPrice Monitoring Extension
17th Nov 20227:00 amRNSCapital Markets Day
15th Nov 202210:36 amRNSPoolbeg-led consortium awarded EUR 2.3m grant
9th Nov 20221:53 pmEQSPoolbeg Pharma makes virus 'breakthrough' using AI drug discovery technology
8th Nov 20227:00 amRNSAI programme yields novel RSV drug targets
21st Oct 20227:00 amRNSUpcoming events participation
6th Oct 20224:40 pmRNSSecond Price Monitoring Extn
6th Oct 20224:35 pmRNSPrice Monitoring Extension
6th Oct 20227:00 amRNSCEO Share Purchase
4th Oct 20227:00 amRNSPOLB 001 US Patent update
21st Sep 20227:00 amRNSPoolbeg licence of Melioidosis vaccine candidate
12th Sep 20227:00 amRNSHC Wainwright Global Investment Conference
6th Sep 20222:05 pmRNSSecond Price Monitoring Extn
6th Sep 20222:00 pmRNSPrice Monitoring Extension
6th Sep 20227:00 amRNSInterim Results
31st Aug 20227:25 amRNSNotice of Results
29th Jul 20227:00 amRNSAppointment of Joint Broker
20th Jul 20227:00 amRNSPOLB001 human challenge clinical trial to commence
12th Jul 20222:06 pmRNSSecond Price Monitoring Extn
12th Jul 20222:00 pmRNSPrice Monitoring Extension
27th Jun 20227:00 amRNSProject update for AI model of RSV data
21st Jun 20224:40 pmRNSSecond Price Monitoring Extn
21st Jun 20224:36 pmRNSPrice Monitoring Extension
26th May 20222:05 pmRNSSecond Price Monitoring Extn
26th May 20222:00 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.